Evidence map›Paper›PMID 37312169›Full record

ArticleCritical care (London, England)2023

Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis.

Carrie M Rosenberger, Katherine D Wick, Hanjing Zhuo, Nelson Wu, Yue Chen, Sharookh B Kapadia, Alessander Guimaraes, Diana Chang, David F Choy, Hubert Chen and 13 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07715110 (Biological and Immunomodulatory Effect of Hemoadsorption With Macroporous Resin Cartridges in Septic Shock and Refractory Septic Shock Two Parallel Open-label Randomized Pilot Trials.), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07715110 nanot yet recruitingnot on this mapstarted 2027, after this paper: background citation

Biological and Immunomodulatory Effect of Hemoadsorption With Macroporous Resin Cartridges in Septic Shock and Refractory Septic Shock Two Parallel Open-label Randomized Pilot Trials.

TypeinterventionalSponsorMiguel Sanchez GarciaRan2027 to 2029Enrolled16ConditionsSeptic Shock, Vasopressor Resistance, Multiple Organ Dysfunction, Sepsis, HemoperfusionArmsHemoadsorption cartridge
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 36 citations in OpenAlex.

  1. Diminished plasma levels of GPIb-Frontiers in medicine · 2026
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Early Dysregulation of Angiopoietin-1 and -2 as a Predictor of Mortality in Critically Ill Burn Patients.Journal of burn care & research : official publication of the American Burn Association · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 2 countries.

Carrie M Rosenberger *Human Pathophysiology and OMNI Reverse Translation, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. rosenbc4@gene.com.
Katherine D WickDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Hanjing ZhuoDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Nelson WuDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Yue ChenDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Sharookh B KapadiaInfectious Diseases, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.
Alessander GuimaraesHuman Pathophysiology and OMNI Reverse Translation, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Diana ChangHuman Genetics, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.
David F ChoyHuman Pathophysiology and OMNI Reverse Translation, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Hubert ChenEarly Clinical Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.
Melicent PeckEarly Clinical Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA.
Kathryn M SullivanDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Serena KeDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Alejandra JaureguiDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Aleksandra LeligdowiczDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Pratik SinhaDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Antonio D GomezDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Kirsten N KangelarisDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Kevin DelucchiDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Kathleen D LiuDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Carolyn S CalfeeDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Michael A MatthayDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA, USA.
Carolyn M Hendrickson *Zuckerberg San Francisco General, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, 1001 Potrero Ave, San Francisco, CA, 94110, USA. Carolyn.hendrickson@ucsf.edu.
University of California, San Francisco · USUniversity of California System · US

Funding

Precision Medicine in the Acute Respiratory Distress SyndromeR35HL140026 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALFEE, CAROLYN · 2018 to 2024
$6.8M
NHLBI NIH HHS R35 HL140026NIH HHS R35HL140026
6 · The paper itself

Abstract

Angiopoietin-2 (Ang-2) is associated with vascular endothelial injury and permeability in the acute respiratory distress syndrome (ARDS) and sepsis. Elevated circulating Ang-2 levels may identify critically ill patients with distinct pathobiology amenable to targeted therapy. We hypothesized that plasma Ang-2 measured shortly after hospitalization among patients with sepsis would be associated with the development of ARDS and poor clinical outcomes. To test this hypothesis, we measured plasma Ang-2 in a cohort of 757 patients with sepsis, including 267 with ARDS, enrolled in the emergency department or early in their ICU course before the COVID-19 pandemic. Multivariable models were used to test the association of Ang-2 with the development of ARDS and 30-day morality. We found that early plasma Ang-2 in sepsis was associated with higher baseline severity of illness, the development of ARDS, and mortality risk. The association between Ang-2 and mortality was strongest among patients with ARDS and sepsis as compared to those with sepsis alone (OR 1.81 vs. 1.52 per log Ang-2 increase). These findings might inform models testing patient risk prediction and strengthen the evidence for Ang-2 as an appealing biomarker for patient selection for novel therapeutic agents to target vascular injury in sepsis and ARDS.

Indexed as

COVID-19Respiratory Distress SyndromeSepsisAngiopoietin-2Critical IllnessHumansPandemicsPrognosisVesicular Transport ProteinsAngiopoietin-2Vesicular Transport ProteinsVPS51 protein, human

Identifiers

PMID37312169
PMCPMC10261831
OpenAlexW4380485545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.